Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylprednisolone liposomal - EnhanX Biopharm

Drug Profile

Methylprednisolone liposomal - EnhanX Biopharm

Alternative Names: 2B3-201; Brain-targeted methylprednisolone - 2-BBB Medicines; ENX-201; Glutathione PEGylated-liposomal methylprednisolone - 2-BBB Medicines

Latest Information Update: 23 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator to-BBB technologies
  • Developer 2-BBB Medicines
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antirheumatics; Glucocorticoids; Pregnadienetriols
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis
  • No development reported CNS disorders

Most Recent Events

  • 23 Jan 2020 Pharmacodynamics data from a preclinical study in Multiple sclerosis presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 24th Annual Conference of Rehabilitation in MS (ECTRIMS-2019)
  • 11 Sep 2019 Clinical development is still ongoing for Multiple sclerosis
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Multiple-sclerosis in Netherlands (IV, Liposomal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top